Literature DB >> 4028007

Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice.

K M Hwang, O Fodstad, R K Oldham, A C Morgan.   

Abstract

A murine monoclonal antibody (9.2.27), directed to a Mr 250,000 glycoprotein-chondroitan sulfate proteoglycan complex, was radiolabeled with 125I and assessed for radiolocalization in tumor and normal tissues of normal and tumor-bearing nude mice. The 125I-9.2.27 localized in vivo preferentially in Mr 250,000 antigen-expressing human melanomas (FMX-Met, SESX) but not in low antigen-expressing tumors (LOX-L) xenografted in nude mice. The imaging index of tumor cells was positively correlated with the antigen density of the various melanoma cell lines as measured by flow cytometry. The nonspecific immunoglobulin RPC-5 of the same IgG2a subclass as 9.2.27 did not specifically localize to xenografts of melanoma. The total amount of 125I-9.2.27 accumulated in the tumor was directly correlated with tumor size. However, the specific radioactivity (cpm/g) in smaller tumors was higher than that in larger tumors. Nonspecific uptake and circulating antibody levels differed between normals and tumor-bearers. The organs of the reticuloendothelial system of normal mice accumulated more labeled antibody than did those of tumor bearers, and conversely, tumor bearers had higher levels of circulating labeled antibody in the blood than normals. The circulating labeled antibody in tumor bearers was still monomeric but had no detectable antigen-binding capacity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028007

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.

Authors:  Michael P Brown; Eva Bezak; Barry J Allen
Journal:  Melanoma Manag       Date:  2015-11-24

2.  Human uveal melanoma expresses NG2 immunoreactivity.

Authors:  Y Li; M C Madigan; K Lai; R M Conway; F A Billson; R Crouch; B J Allen
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

3.  Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent.

Authors:  A R Fritzberg; P G Abrams; P L Beaumier; S Kasina; A C Morgan; T N Rao; J M Reno; J A Sanderson; A Srinivasan; D S Wilbur
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

4.  Human parathyroid antigen: characterization and localization with monoclonal antibodies.

Authors:  W G Cance; S A Wells; W G Dilley; M J Welch; F L Otsuka; J M Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 5.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  The detection of virally induced tumors by 131I- and 125I-labeled syngeneic monoclonal antibodies.

Authors:  D Berends; J L van Gaalen; E H Rhijnsburger; N J de Both; W Breeman; W H Bakker; P Kooy
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells.

Authors:  A Godal; O Bruland; E Haug; M Aas; O Fodstad
Journal:  Br J Cancer       Date:  1986-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.